Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600800 | PMC |
| http://dx.doi.org/10.1016/j.mycmed.2021.101228 | DOI Listing |
Publication Analysis
Top Keywords
immunocompromised patient
8
covid-19 associated
8
capa cam
8
cam
5
pulmonary mucormycosis
4
mucormycosis aftermath
4
aftermath critical
4
covid-19
4
critical covid-19
4
covid-19 immunocompromised
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!